

3-30-06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1FW

Applicants:

Angelika Bodenteich et al.

Attorney Docket: SAN1008US

Serial No.:

10/537,568

Group Art Unit: 1614

Filed:

July 15, 2005

For:

USE OF GALANTHAMINE AND THE DERIVATIVES THEREOF IN THE

PRODUCTION OF MEDICAMENTS

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith are the following:

- 1. Supplemental Information Disclosure Statement (2 pages);
- 2. Form 1449 listing 34 documents (2 pages); and
- 3. Copies of the non-U.S. listed documents (26 documents).

Please charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 16-2312.

Dated: March 29, 2016

Respectfully submitted,

Customer No. 009561

Patrick J. O'Connell (33,984)

POPOVICH, WILES & O'CONNELL, P.A.

650 Third Avenue South, Suite 600

Minneapolis, MN 55402 Telephone: (612) 334-8989

Attorney for Applicants

Certificate of Express Mailing (37 C.F.R. § 1.10)

I hereby certify that this paper or fee is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Mailing Label No. <u>EV 769991644 US</u> in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: March 29, 2006

Signature:

Name: Joef Jung

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Angelika Bodenteich et al.

Attorney Docket: SAN1008US

Serial No.:

10/537,568

Group Art Unit: 1614

Filed:

July 15, 2005

For:

USE OF GALANTHAMINE AND THE DERIVATIVES THEREOF

IN THE PRODUCTION OF MEDICAMENTS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to Sections 1.56, 1.97, and 1.98 of Title 37 of the Code of Federal Regulations, the following information is set forth in compliance with Applicants' duty of disclosure, as well as the duty of others substantively involved in the preparation of the above-titled application.

The Applicants and others substantively involved in the preparation of the application are aware of the documents cited on the enclosed PTO-1449 form. Copies of the non-U.S. documents are enclosed. International Application No. PCT/AT2004/000309, published as WO 2005/030333 A2, was extended into the United States on March 24, 2006. This application and the subject application both claim the priority of Austrian Patent Application No. A 1538/2003.

Certificate of Express Mailing (37 C.F.R. § 1.10)

I hereby certify that this paper or fee is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Mailing Label No. EV 769991644 US in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1380 on the gate indicated below.

Date: March 29, 2006 Signature:

Supplemental Information Disclosure Statement Attorney Docket: SAN1008US

Applicants: Angelika Bodenteich et al.

Serial Number: 10/537,568

The present statement reflects the direct knowledge of the undersigned and information disclosed to the undersigned by the Applicants and others substantively involved in the preparation of the present application pursuant to their duty under 37 C.F.R. § 1.56.

Applicants reserve the right to show, pursuant to 37 C.F.R. § 1.131 or otherwise, that any one or more of the documents cited on the PTO-1449 form is not prior art to the present invention.

Pursuant to the Manual of Patent Examining Procedure, Chapter 609, Applicants request that the Examiner consider each of the listed documents and initial and return to the undersigned a copy of the enclosed PTO-1449 form.

It is believed that no fees are due in connection with this submission. However if this is incorrect, please charge any additional fees to Deposit Account Number 16-2312.

Respectfully submitted,

Date: March 29, 2006

Customer No. 009561

Patrick J. O'Connell (33,984)

POPOVICH, WILES &

O'CONNELL, P.A.

650 Third Avenue South, Suite 600

Minneapolis, MN 55402 Telephone: (612) 334-8989 Attorney for Applicants

MAR 2 9 2006 STA

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
SAN1008US	10/537,568
	10/33/,300
APPLICANTS	
=	
Angelika Bodenteich et al.	
FILING DATE	GROUP
I ILING DATE	GROOF
July 15, 2005	1614
July 10, 2000	1 1017

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER					ER		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5	9	5	8	9	0	3	09/28/99	Renko et al.			
	6	0	4	3	3	5	9	03/28/00	Czollner et al.			
	6	3	6	9	2	3	8	04/09/02	Czollner et al.			
	6	4	0	7	2	2	9	06/18/02	Czollner et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	LATION NO
 	WO 2005/030333 A2	04/07/05	WIPO	1		Х	
	WO 2005/030333 A3	04/07/05	WIPO			·	
	WO 01/74820 A1	10/11/01	WIPO				X
	WO 01/74820 A1 (abstract only)	10/11/01	WIPO				
-	WO 00/32199	06/08/00	WIPO				X
	WO 00/32199 (abstract only)	06/08/00	WIPO				
	WO 00/32185	06/08/00	WIPO				X
	WO 00/32185 (abstract only)	06/08/00	WIPO				
	WO 97/40049	10/30/97	WIPO				X
	WO 97/40049 (abstract only)	10/30/97	WIPO				
	WO 97/03987	02/06/97	WIPO				X
	WO 97/03987 (abstract only)	02/06/97	WIPO				
	WO 96/12692	05/02/96	WIPO				X
	WO 96/12692 (abstract only)	05/02/96	WIPO				
	NL 8 800 350 A	09/01/89	Netherlands				X
	NL 8 800 350 A (abstract only)	09/01/89	Netherlands				
	FR 2 826 005	12/20/02	France				X
	FR 2 826 005 (abstract only)	12/20/02	France				
				-			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	U.S. Patent Application Publication No. 2005/0065338 A1, published March 24, 2005,
	Thal et al.
	U.S. Patent Application Publication No. 2004/0067974 A1, published April 8, 2004,
	Czollner et al.
	U.S. Patent Application Publication No. 2003/0199493 A1, published October 23, 2003,
	Jordis et al.
	U.S. Patent Application Publication No. 2003/0092700 A1, published May 15, 2003,
	Czollner et al.
	Bhandarkar et al., "Structure and Biosynthesis of Chlidanthine," <u>Journal of the</u>
	Chemical Society, Section C: Organic Chemistry, Chemical Society. Letchworth, GB,
	no. 9, pages 1224-1227 (1970).
	Bartolucci et al., "Three-Dimensional Structure of a Complex of Galanthamine (Nivalin)
	with Acetylcholinesterase from <i>Torpedo californica</i> : Implications for the Design of New
	Anti-Alzheimer Drugs," <u>PROTEINS</u> : Structure, Function and Genetics, 42(2):182-191
	(2001).
	Bastida et al., "Alkaloids from Narcissus Leonensis," Phytochemistry, Pergamon Press,
	GB, 34(6):1656-1658 (1993).
	Li et al., "Alkaloids of <i>Lycoris guangxiensis</i> ," <u>Planta Medica</u> , Thieme, Stuttgart, DE, 53(3):259-261 (1987).
	Mutschler et al., "Arzneimittelwirkungen," 2001, WVG, Stuttgart, page 195, column 2,
	paragraph 1.
	Pilger et al., "Accurate Prediction of the Bound Conformation of Galanthamine in the
	Active Site of <i>Torpedo californica</i> Acetylcholinesterase Using Molecular Docking,"
	Journal of Molecular Graphics and Modelling, Elsevier Science, New York, NY, US,
	19(3/4):288-296 (2001).
	Recanatini et al., "Acetylcholinesterase Inhibitors in the Context of Therapeutic
}	Strategies to Combat Alzheimer's Disease," Expert Opinion on the Therapeutic
	Patents, Ashley Publications, GB, 12(12):1853-1865 (2002).
	Vlahov et al., "Synthesis of Galanthamine and Related Alkaloids-New Approaches. I",
	Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, 45(11):3329-3345 (1989).
EYAMINED	DATE CONSIDERED

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.